Aleniglipron Pill Delivers 12% Weight Loss in Phase II Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Aleniglipron, an oral small-molecule GLP-1 drug, delivered dose-dependent weight loss over 36 weeks in 230 adults with obesity or overweight: -9.0% at 45mg, -10.7% at 90mg, and -12.1% at 120mg, versus -0.5% for placebo.
- The randomized, double-blind, placebo-controlled Phase II trial ran at 38 U.S. medical centers with participants averaging 50 years old, and results were published in Nature Medicine.
- Robert Kushner, MD, professor emeritus of Medicine at Northwestern and a co-author, highlighted that aleniglipron is chemically synthesized, taken once daily with or without food, and could potentially be combined with other medications.
- Unlike injectable peptide-based GLP-1 drugs such as Ozempic and Wegovy, aleniglipron is a small molecule that avoids refrigeration requirements and may be easier and cheaper to manufacture at scale, addressing access barriers.
- Gastrointestinal side effects were generally mild to moderate and decreased over the study; 10.4% of participants discontinued treatment, and researchers reported no cases of drug-induced liver injury.
- Structure Therapeutics funded the work, and Kushner said a Phase III trial is planned with a slower dose escalation to improve tolerability.
Why it matters: If aleniglipron clears Phase III and wins approval, the oral, refrigerator-free, small-molecule design could loosen the manufacturing and access bottlenecks that have constrained injectable GLP-1 supply — putting pressure on peptide-based incumbents like Ozempic and Wegovy on convenience and cost.
Ask SkimNews
